About us

Avexxin Oncology AS  is established as a Norwegian subsidiary company to the Swedish biotechnology company Coegin Pharma AB as part of Coegin Pharma AB’s hub & spoke “portfolio” biotech model, with clear benefits to investors. Avexxin Oncology AS will develop the promising novel and proprietary cancer drug candidate AVX420 further, and will primarily be financed separately from Coegin Pharma AB.

Management and Board of Directors

An experienced team with a strong track record, broad Nordic outreach and key competences 

John R. Zibert

Chief Executive Officer

  • Extensive experience in drug discovery and development
  • Chief Medical Officer at Coegin Pharma AB
  • Former founder and CEO at the digital CRO Studies&Me, Chief Medical Officer at LEO Innovation Lab, Head of Medical Affairs EU+ LEO Pharma A/S
  • Ph.D. in immunology, M.Sc. human biology/medicine, with academic focus within Dermatology, Oncology, Cancer Biology, and digital health solutions
  • Vast experience in clinical study design and execution, dermatology, oncology, research and development, innovation processes and medical affairs
send e-mail

Erlend P. Skagseth

Board Member

  • Currently, Managing Partner, Sarsia Seed AS
  • Former experience from Christian Mikkelsen Research, Forinnova, and Sarsia Innovation
  • Vast experience in turnarounds, licensing and exits
  • Board Member of Coegin Pharma AB

Thoas Fioretos

Board Member

  • Leading expert in the field of leukemia
  • Professor at the Department of Clinical Genetics at Lund University
  • Co-founder & Board Member Cantargia AB
  • Co-founder & Board Member Qlucore AB
  • Vast experience in cancer research with a focus on leukemia
  • Board Member of Coegin Pharma AB